Ribosomal RNA Degradation (RNA Disruption) in Tumour Cells: Mechanistic Insights and Potential Clinical Utility

Area of Science:

• Molecular Biology
• Cancer Research
• Cellular Biology

Background:

• Ribosomes are essential for protein synthesis and are upregulated in cancers.
• Tumor cells undergo ribosomal RNA degradation, termed "RNA disruption," when exposed to stressors or anti-cancer agents.
• This phenomenon is observed both in vitro and in vivo.

Purpose of the Study:

• To review the cellular processes of chemotherapy-induced RNA disruption.
• To discuss clinical studies on tumor RNA disruption in cancer patients.
• To explore the clinical utility of the RNA disruption assay (RDA) in managing breast cancer patients.

Main Methods:

• The RNA disruption assay (RDA) quantifies ribosomal RNA degradation in tumor cells.
• RDA can be applied to cultured cell lines and patient samples.
• The assay distinguishes between dying and arrested tumor cells, unlike other drug sensitivity assays.

Main Results:

• Low tumor RNA disruption during neoadjuvant chemotherapy correlates with residual disease and reduced disease-free survival.
• High RNA disruption may indicate chemo-responsiveness.
• RDA shows potential as a chemo-resistance assessment tool.

Conclusions:

• RDA is a valuable tool for anti-cancer drug discovery and development.
• RDA can guide the escalation or de-escalation of neoadjuvant chemotherapy.
• RDA may facilitate adaptive clinical trials and regulatory drug approval.